Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HELIOS
2023-509637-39-00Phase 4Authorised
- Sponsor
- Ghent University Hospital
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of secukinumab, ixekizumab and guselkumab in plaque psoriasis (2 arms), sponsored by Ghent University Hospital. Primary endpoint: Sustained disease control over 18 months. Planned start Aug 2024; status: authorised.
02
Drugs
secukinumabixekizumabguselkumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2023-509637-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509637-39-00.